Recent efforts to map human genetic variation through sequencing exomes^[@R1]^ and whole genomes^[@R2]-[@R4]^ have characterised the vast majority of common SNPs and many structural variants across the genome. However, while over 95% of common (\>5% frequency) variants were discovered in the Pilot Phase of the 1000 Genomes Project, lower-frequency variants, particularly outside the coding exome, remain poorly characterised. Low-frequency variants are enriched for potentially functional mutations, for example protein-changing variants, under weak purifying selection^[@R1],[@R5],[@R6]^. Furthermore, low-frequency variants, because they tend to be recent in origin, exhibit increased levels of population differentiation^[@R6]-[@R8]^. Characterising such variants, for both point mutations and structural changes, across a range of populations is thus likely to identify many variants of functional significance and is critical in interpreting individual genome sequences; for example to help separate shared variants from those private to families.

We now report on the genomes of 1,092 individuals sampled from 14 populations drawn from Europe, East Asia, sub-Saharan Africa and the Americas ([Figs. S1](#SD1){ref-type="supplementary-material"},[S2](#SD1){ref-type="supplementary-material"}), analysed through a combination of low-coverage (2-6x) whole-genome sequence (WGS) data, targeted deep exome sequence data (50-100x) and dense SNP genotype data ([Tables 1](#T1){ref-type="table"}, [S1](#SD1){ref-type="supplementary-material"}-[S3](#SD1){ref-type="supplementary-material"}). This design was shown by the Pilot Phase^[@R2]^ to be powerful and cost-effective in discovering and genotyping all but the rarest SNP and short insertion and deletion (indel) variants. Here, the approach was augmented with statistical methods for selecting higher quality variant calls from candidates obtained using multiple algorithms and to integrate SNP, indel and larger structural variants (SVs) within a single framework (see [Box](#BX1){ref-type="boxed-text"} and [Fig. S1](#SD1){ref-type="supplementary-material"}). Because of the challenges of identifying large and complex structural variants and shorter indels in regions of low complexity, we focused on conservative but high quality subsets: biallelic indels and large deletions.

Overall, we discovered and genotyped 38 million SNPs, 1.4 million bi-allelic indels and 14 thousand large deletions ([Table 1](#T1){ref-type="table"}). Multiple technologies were used to validate a frequency-matched set of sites to assess and control the false discovery rate (FDR) for all variant types. Where results were clear, 3/185 exome sites (1.6%), 5/281 low-coverage sites (1.8%) and 72/3415 (2.1%) large deletions could not be validated ([Supplementary Information and Tables S4](#SD1){ref-type="supplementary-material"}-[S9](#SD1){ref-type="supplementary-material"}). The initial indel call-set was found to have a high FDR (27/76), which led to the application of additional filters, leaving an implied FDR of 5.4% ([Table S6](#SD1){ref-type="supplementary-material"}; [Supplementary Information](#SD1){ref-type="supplementary-material"}). Moreover, for 2.1% of low-coverage SNP and 18% of indel sites we found inconsistent or ambiguous results indicating the substantial challenges remaining in characterising variation in low-complexity genomic regions. We previously described the "accessible genome": the fraction of the reference genome where short-read data can lead to reliable variant discovery. Through longer read-lengths the fraction accessible has increased from 85% in the Pilot to 94% (available as a genome annotation; see [Supplementary Information](#SD1){ref-type="supplementary-material"}) and 1.7 million low-quality SNPs from the Pilot Phase have been eliminated.

By comparison to external SNP and high-depth sequencing data, we estimate the power to detect SNPs present at a frequency of 1% in the study samples is 99.3% across the genome and 99.8% in the consensus exome target ([Fig. 1a](#F1){ref-type="fig"}). Moreover, the power to detect SNPs at 0.1% frequency in the study is over 90% in the exome and nearly 70% across the genome. The accuracy of individual genotype calls at heterozygous sites is over 99% for common SNPs and 95% for SNPs at frequency of 0.5% ([Fig. 1b](#F1){ref-type="fig"}). By integrating LD information, genotypes from low-coverage data are as accurate as those from high depth exome data for SNPs with frequency \>1%. For very rare SNPs (≤0.1%, therefore present in 1 or 2 copies), there is no gain in genotype accuracy from incorporating LD information and accuracy is lower. Variation among samples in genotype accuracy is primarily driven by sequencing depth ([Fig. S3](#SD1){ref-type="supplementary-material"}) and technical issues such as sequencing platform and version (detectable by PCA; [Fig. S4](#SD1){ref-type="supplementary-material"}) rather than population-level characteristics. The accuracy of inferred haplotypes at common SNPs was estimated by comparison to SNP data collected on mother-father-offspring trios for a subset of the samples. This indicates that a phasing (switch) error is made, on average, every 300-400 kb ([Fig. S5](#SD1){ref-type="supplementary-material"}).

A key goal of the 1000 Genomes Project was to identify over 95% of SNPs at 1% frequency in a broad set of populations. Our current resource includes \~50%, 98% and 99.7% of the SNPs with frequencies of \~0.1%, 1.0% and 5.0% respectively in \~2,500 UK-sampled genomes (the Wellcome Trust-funded UK10K project), thus meeting this goal. However, coverage may be lower for populations not closely related to those studied. For example, our resource includes only 23.7%, 76.9% and 99.3% of the SNPs with frequencies of \~0.1%, 1.0% and 5.0% respectively in \~2,000 genomes sequenced in a study of the isolated population of Sardinia (the SardiNIA study).

###### Constructing an integrated map of variation

The 1,092 haplotype-resolved genomes released as Phase 1 by the 1000 Genomes Project are the result of integrating diverse data from multiple technologies generated by several centres between 2008 and 2010. The figure describes the process leading from primary data production to integrated haplotypes. **a**. Unrelated individuals (though see [Table S10](#SD1){ref-type="supplementary-material"}) were sampled in groups of up to 100 from related populations (Wright's F~ST~ typically \<1%) within broader geographical or ancestry-based groups^[@R2]^. Primary data generated for each sample consist of low-coverage (average 5x) whole-genome and high-coverage exome (average 80x across a consensus target of 24 Mb spanning over 15,000 genes) sequence data and high density SNP array information. **b**. Following read-alignment, multiple algorithms were used to identify candidate variants. For each variant, quality metrics were obtained, including information about uniqueness of the surrounding sequence (e.g., mapping quality), the quality of evidence supporting the variant (e.g., the position of variant bases within reads), and the distribution of variant calls in the population (e.g,. inbreeding coefficient). Machine-learning approaches using this multidimensional information were trained on sets of high-quality known variants (e.g., the high-density SNP array data), allowing variants sites to be ranked in confidence and subsequently thresholded to ensure low FDR. **c**. Genotype likelihoods were used to summarise the evidence for each genotype at bi-allelic sites (0, 1 or 2 copies of the variant) in each sample at every site. **d**, As the evidence for a single genotype is typically weak in the low-coverage data, and can be highly variable in the exome data, statistical methods were used to leverage information from patterns of linkage disequilibrium, allowing haplotypes (and genotypes) to be inferred.

The distribution of genetic variation within and between populations {#S2}
====================================================================

The integrated data set provides a detailed view of variation across multiple populations (illustrated in [Fig. 2a](#F2){ref-type="fig"}). Most common variants (94% of variants with frequency ≥5% in the figure) were known prior to the current phase of the project and had their haplotype structure mapped through earlier projects^[@R2],[@R9]^. In contrast, only 62% of variants in the range 0.5-5% and 13% of variants with frequency ≤ 0.5% had been described previously. For analysis, populations are grouped by the predominant component of ancestry: Europe (CEU, TSI, GBR, FIN, IBS), Africa (YRI, LWK, ASW), East Asia (CHB, JPT, CHS) and the Americas (MXL, CLM, PUR). Variants present at 10% and above across the entire sample are almost all found in all populations studied. In contrast, 17% of low-frequency variants in the range 0.5-5% were observed in a single ancestry group and 53% of rare variants at 0.5% were observed in a single population ([Fig. 2b](#F2){ref-type="fig"}). Within ancestry groups, common variants are weakly differentiated (most within-group estimates of *F*~ST~ are \< 1%; [Table S11](#SD1){ref-type="supplementary-material"}), although below 0.5% frequency variants are up to twice as likely to be found within the same population compared to random sample from the ancestry group ([Fig. S6a](#SD1){ref-type="supplementary-material"}). The degree of rare-variant differentiation varies between populations. For example, within Europe, the IBS and FIN populations carry excesses of rare variants ([Fig. S6b](#SD1){ref-type="supplementary-material"}), which can arise through events such as recent bottlenecks^[@R10]^, 'clan' breeding structures^[@R11]^ and admixture with diverged populations^[@R12]^.

Some common variants show strong differentiation between populations within ancestry-based groups ([Table S12](#SD1){ref-type="supplementary-material"}), many of which are likely to have been driven by local adaptation either directly or through hitch-hiking. For example, the strongest differentiation between AFR populations is in NRSF transcription-factor peak (PANC1-cell-line)^[@R13]^ upstream of *ST8SIA1* (difference in derived allele frequency LWK-YRI of 0.475 at rs7960970), whose product is involved in ganglioside generation^[@R14]^. Overall, we find a range of 17-343 SNPs (fewest = CEU-GBR, most = FIN-TSI) showing a difference in frequency of at least 0.25 between pairs of populations within an ancestry-group.

The derived allele frequency distribution shows substantial divergence between populations below a frequency of 40% ([Fig. 2c](#F2){ref-type="fig"}), such that individuals from populations with substantial African ancestry (YRI, LWK, ASW) carry up to three times as many low-frequency variants (0.5-5% frequency) as those of European or East Asian origin, reflecting ancestral bottlenecks in non-African populations^[@R15]^. However, individuals from all populations show an enrichment of rare (\<0.5%) variants, reflecting recent explosive increases in population size and the effects of geographic differentiation^[@R6],[@R16]^. Compared to the expectations from a model of constant population size, individuals from all populations show a substantial excess of high-frequency derived variants (\>80% frequency).

Because rare variants are typically recent, their patterns of sharing can reveal aspects of population history. Variants present twice across the entire sample (referred to as *f*~2~ variants), typically the most recent of informative mutations, are found within the same population in 53% of cases ([Fig. 3a](#F3){ref-type="fig"}). However, between-population sharing identifies recent historical connections. For example, where one of the individuals carrying an *f*~2~ variant is from the Spanish population (IBS) and the other is not (referred to as IBS-X), the other individual is more likely to come from the AMR populations (48%, correcting for sample size) than elsewhere in Europe (41%). Within the East Asian populations, CHS and CHB show stronger *f*~2~ sharing to each other (58% and 53% of CHS-X and CHB-X variants respectively) than either does to JPT, but JPT is closer to CHB than to CHS (44% versus 35% of JPT-X variants). Within African-ancestry populations, the ASW are closer to the YRI (42% of ASW-X *f*~2~ variants) compared to the LWK (28%), in line with historical information^[@R17]^ and genetic evidence based on common SNPs^[@R18]^. Some sharing patterns are surprising; for example, 2.5% of the *f*~2~ FIN-X variants are shared with YRI or LWK populations.

Independent evidence about variant age comes from the length of the shared haplotypes on which they are found. We find, as expected, a negative correlation between variant frequency and the median length of shared haplotypes, such that chromosomes carrying variants at 1% frequency share haplotypes of 100-150 kb (typically 0.08-0.13 cM; [Figs. 3b](#F3){ref-type="fig"} and [S7a](#SD1){ref-type="supplementary-material"}), although the distribution is highly skewed and 2-5% of haplotypes around the rarest SNPs extend over 1 Mb ([Figs. S7b,c](#SD1){ref-type="supplementary-material"}). Haplotype phasing and genotype calling errors will limit the ability to detect long shared haplotypes and the observed lengths are a factor of 2-3 shorter than predicted by models that allow for recent explosive growth^[@R6]^ ([Fig. S7a](#SD1){ref-type="supplementary-material"}). Nevertheless, the haplotype length for variants shared within and between populations is informative about relative allele age. Within populations and between populations where there is recent shared ancestry (e.g., through admixture and within continents) *f*~2~ variants typically lie on long shared haplotypes (median within ancestry group 103 kb, [Fig. S8](#SD1){ref-type="supplementary-material"}). In contrast, between populations with no recent shared ancestry, *f*~2~ variants are present on very short haplotypes, for example, an average of 11 kb for FIN-YRI *f*~2~ variants (median between ancestry groups excluding admixture is 15 kb), and are therefore likely to reflect recurrent mutations and chance ancient coalescent events.

To analyse populations with substantial historical admixture, statistical methods were applied to each individual to infer regions of the genome with different ancestries. Populations and individuals vary substantially in admixture proportions. For example, the MXL population contains the greatest proportion of Native American ancestry (47% on average compared to 24% in CLM and 13% in PUR), but the proportion varies from 3% to 92% between individuals ([Fig. S9a](#SD1){ref-type="supplementary-material"}). Rates of variant discovery, the ratio of nonsynonymous to synonymous variation and the proportion of variants that are novel vary systematically between regions with different ancestries. Regions of Native American ancestry show less variation, but a higher fraction of the variants discovered are novel (3.0% of variants per sample, [Fig. 3c](#F3){ref-type="fig"}) compared to regions of European ancestry (2.6%). Regions of African ancestry show the highest rates of novelty (6.2%) and heterozygosity ([Fig. S9b,c](#SD1){ref-type="supplementary-material"}).

The functional spectrum of human variation {#S3}
==========================================

The Phase 1 data enable us to compare, for different genomic features and variant types, the effects of purifying selection on evolutionary conservation^[@R19]^, the allele frequency distribution and the level of differentiation between populations. At the most highly conserved coding sites, 85% of nonsynonymous (NonSyn) variants and over 90% of STOP gain and splice-disrupting variants are below 0.5% in frequency , compared to 65% of synonymous (Syn) variants ([Fig. 4a](#F4){ref-type="fig"}). In general, the rare variant excess tracks the level of evolutionary conservation for variants of most functional consequence, but varies systematically between types (e.g., for a given level of conservation enhancer variants have a higher rare variant excess than variants in transcription factor motifs). However, STOP gains and, to a lesser-extent, splice-site disrupting changes, show elevated rare-variant excess whatever the conservation of the base in which they occur, as such mutations can be highly deleterious whatever the level of sequence conservation. Interestingly, the least conserved splice-disrupting variants show rare-variant load similar to synonymous and non-coding regions suggesting that these alternative transcripts are under very weak selective constraint. Sites at which variants are observed are typically less conserved than average (for example, sites with NonSyn variants are, on average, as conserved as third codon positions, [Fig S10](#SD1){ref-type="supplementary-material"}).

A simple way of estimating the segregating load arising from rare, deleterious mutations across a set of genes comes from comparing the ratios of NonSyn to Syn variants in different frequency ranges. The NonSyn to Syn ratio among rare (\<0.5%) variants is typically in the range 1-2 and among common variants in the range 0.5-1.5, suggesting that 25-50% of rare NonSyn variants are deleterious. However, the segregating rare load among gene groups in KEGG pathways^[@R20]^ varies substantially ([Fig. S11a](#SD1){ref-type="supplementary-material"}; [Table S13](#SD1){ref-type="supplementary-material"}). Certain groups (e.g., ECM-receptor interaction, DNA replication and pentose phosphate pathway) show a substantial excess of rare coding mutations, which is only weakly correlated with the average degree of evolutionary conservation. Pathways and processes showing an excess of rare functional variants vary between continents ([Fig. S11b](#SD1){ref-type="supplementary-material"}). Moreover, the excess of rare NonSyn variants is typically higher in populations of European and East Asian ancestry (for example, the ECM-receptor interaction pathway load is strongest in EUR). Other groups of genes (for example, those associated with allograft rejection) actually have a high NonSyn:Syn ratio in common variants, potentially indicating the effects of positive selection.

Genome-wide data provide important insights into the rates of functional polymorphism in the non-coding genome. For example, we consider motifs matching the consensus for transcriptional repressor CTCF, which has a well-characterised and highly conserved binding motif^[@R21]^. Within CTCF-binding peaks experimentally defined by chromatin-immunoprecipitation sequencing (ChIP-seq), average levels of conservation within the motif are comparable to third codon positions, while outside peaks there is no conservation ([Fig. 4c](#F4){ref-type="fig"}). Within peaks levels of genetic diversity are typically reduced 25-75%, depending on the position in the motif ([Fig. 4c](#F4){ref-type="fig"}). Unexpectedly, the reduction in diversity at some degenerate positions, for example position 8 in the motif, is as great as that at nondegenerate positions, suggesting that motif degeneracy may not have a simple relationship with functional importance. Variants within peaks show a weak but consistent excess of rare variation (proportion with frequency \<0.5% is 61% within peaks compared to 58% outside peaks, [Fig. S12](#SD1){ref-type="supplementary-material"}) supporting the hypothesis that regulatory sequences harbour substantial amounts of weakly deleterious variation.

Purifying selection can also affect population differentiation if its strength and efficacy vary among populations. Although the magnitude of the effect is weak, nonsynonymous variants consistently show greater levels of population differentiation than synonymous variants, for variants of frequency less than 10% ([Fig. S13](#SD1){ref-type="supplementary-material"}).

Uses of 1000 Genomes Project data in medical genetics {#S4}
=====================================================

Data from the 1000 Genomes Project are widely used to screen variants discovered in exome data from individuals with genetic disorders^[@R22]^ and in cancer genome projects^[@R23]^. The enhanced catalogue presented here improves the power of such screening. Moreover, it provides a 'null expectation' for the number of rare, low-frequency and common variants with different functional consequences typically found in randomly-sampled individuals from different populations.

Estimates of the overall numbers of variants with different sequence consequences are comparable to previous values ^[@R1],[@R20]-[@R22]^ ([Table S14](#SD1){ref-type="supplementary-material"}). However, only a fraction of these are likely to be functionally-relevant. A more accurate picture of the number of functional variants is given by the number of variants segregating either at conserved positions (here defined as sites with a GERP^[@R19]^ conservation score of \>2), or where the function (e.g., STOP gain) is strong and independent of conservation ([Table 2](#T2){ref-type="table"}). We find that individuals typically carry over 2,500 nonsynonymous variants at conserved positions, 20-40 variants identified as damaging^[@R24]^ at conserved sites and about 150 loss-of-function variants (LOF: STOP gains, frameshift indels in coding sequence and disruptions to essential splice-sites). However, most of these are common (\>5%) or low-frequency (0.5-5%) such that the numbers of rare (\<0.5%) variants in these categories (which might be considered as pathological candidates) are much lower; 130-400 nonsynonymous variants per individual, 10-20 LOF variants, 2-5 damaging mutations and 1-2 variants identified previously from cancer genome sequencing^[@R25]^. By comparison to synonymous variants, we can estimate the excess of rare variants; those mutations that are sufficiently deleterious that they will never reach high frequency. We estimate that individuals carry an excess of 76-190 rare deleterious nonsynonymous variants and up to 20 LOF and disease-associated variants. Interestingly, the overall excess of low-frequency variants is similar to that of rare variants ([Table 2](#T2){ref-type="table"}). Because many variants contributing to disease risk are likely to be segregating at low frequency, we recommend that variant frequency be considered when using the resource to identify pathological candidates.

The combination of variation data with information about regulatory function^[@R13]^ can potentially improve the power to detect pathological non-coding variants. We find that individuals typically harbour several thousands of variants (and several hundred rare variants) in conserved (GERP conservation score \>2) UTRs, non-coding RNAs and transcription-factor binding motifs ([Table 2](#T2){ref-type="table"}). Within experimentally-defined transcription factor binding sites, individuals carry 700-900 conserved motif losses (for the transcription factors analysed, see [Supplementary Information](#SD1){ref-type="supplementary-material"}), of which 18-69 are rare (\<0.5%) and which show strong evidence for being selected against. Motif gains are rarer (\~200 per individual at conserved sites) but they also show evidence for an excess of rare variants compared to conserved sites with no functional annotation ([Table 2](#T2){ref-type="table"}). Many of these changes are likely to have weak, slightly deleterious effects on gene regulation and function.

A second major use of the 1000 Genomes Project data in medical genetics is imputing genotypes in existing genome-wide association studies (GWAS)^[@R26]^. For common variants, the accuracy of using the Phase 1 data to impute genotypes at sites not on the original GWAS chip is typically 90-95% in non-African and approximately 90% in African-ancestry genomes ([Figs. 5a](#F5){ref-type="fig"}, [S14a](#SD1){ref-type="supplementary-material"}), which is comparable to the accuracy achieved with high quality benchmark haplotypes ([Fig. S14b](#SD1){ref-type="supplementary-material"}). Imputation accuracy is similar for intergenic SNPs, exome SNPs, indels and large deletions (see also [Fig. S14c](#SD1){ref-type="supplementary-material"}), despite the different amounts of information about such variants and accuracy of genotypes. For low-frequency variants (1-5%), imputed genotypes have between 60% and 90% accuracy in all populations, including those with admixed ancestry (also comparable to the accuracy from trio-phased haplotypes; [Fig. S14b](#SD1){ref-type="supplementary-material"}).

Imputation has two primary uses: fine-mapping existing association signals and detecting novel associations. GWAS have had only a few examples of successful fine-mapping to single causal variants^[@R27],[@R28]^, often because of extensive haplotype structure within regions of association^[@R29],[@R30]^. We find that, in Europeans, each previously reported GWAS signal^[@R31]^ is, on average, in linkage disequilibrium (r^2^ ≥ 0.5) with 56 variants: 51.5 SNPs and 4.5 indels. In 19% of cases at least one of these variants changes the coding sequence of a nearby gene (compared to 12% in control variants matched for frequency, distance to nearest gene and ascertainment in GWAS arrays) and in 65% of cases at least one of these is at a site with GERP\>2 (68% in matched controls). The size of the associated region is typically \<200 kb in length ([Figure 5b](#F5){ref-type="fig"}). Our observations suggest that trans-ethnic fine-mapping experiments are likely to be especially valuable: among the 56 variants that are in strong linkage disequilibrium with a typical GWAS signal, \~15 show strong disequilibrium across our four continental groupings ([Table S15](#SD1){ref-type="supplementary-material"}). Compared to earlier catalogs, our current resource increases the number of variants in linkage disequilibrium with each GWAS signal by 25% compared to the Pilot phase of the project and by greater than 2-fold compared to the HapMap resource.

Discussion {#S5}
==========

The success of exome sequencing in Mendelian disease genetics^[@R32]^ and the discovery of rare and low-frequency disease-associated variants in genes associated with complex diseases^[@R27],[@R33],[@R34]^ strongly support the hypothesis that, in addition to factors such as epistasis^[@R35],[@R36]^ and gene-environment interactions^[@R37]^, many additional genetic risk factors of substantial effect size remain to be discovered through studies of rare variation. The data generated by the 1000 Genomes Project not only aid the interpretation of all genetic association studies, but also provide lessons on how best to design and analyse sequencing-based studies of disease.

The utility and cost-effectiveness of collecting multiple data types (low-coverage whole genome sequence, targeted exome data, SNP genotype data) for finding variants and reconstructing haplotypes are demonstrated here. Exome capture provides private and rare variants that are missed by low-coverage data (approximately 60% of the singleton variants in the sample were detected only from exome data compared to 5% only detected from low-coverage data, [Fig. S15](#SD1){ref-type="supplementary-material"}). However, whole-genome data enable characterisation of functional non-coding variation and accurate haplotype estimation, which are essential for the analysis of cis-effects around genes, for example those arising from variation in upstream regulatory regions^[@R38]^. There are also benefits from integrating SNP array data, for example to improve genotype estimation^[@R39]^ and to aid haplotype estimation where array data have been collected on additional family members. In principle, any sources of genotype information (e.g., from array CGH) could be integrated using the statistical methods developed here.

Major methodological advances in Phase 1, including improved methods for detecting and genotyping variants^[@R40]^, statistical and machine-learning methods for evaluating the quality of candidate variant calls, modelling of genotype likelihoods and performing statistical haplotype integration^[@R41]^, have generated a high-quality resource. However, regions of low sequence complexity, satellite regions, large repeats and many large-scale structural variants, including copy-number polymorphisms, segmental duplications and inversions (which constitute most of the "inaccessible genome"), continue to present a major challenge for short-read technologies. Some issues are likely to be improved by methodological developments such as better modelling of read-level errors, integrating *de novo* assembly^[@R42],[@R43]^ and combining multiple sources of information to aid genotyping of structurally-diverse regions^[@R40],[@R44]^. Importantly, even subtle differences in data type, data processing or algorithms may lead to systematic differences in false-positive and false negative error modes between samples. Such differences complicate efforts to compare genotypes between sequencing studies. Moreover, analyses that naively combine variant calls and genotypes across heterogeneous data sets are vulnerable to artifact. Analyses across multiple data sets must therefore either process them in standard ways or use meta-analysis approaches that combine association statistics (but not raw data) across studies.

Finally, the analysis of low-frequency variation demonstrates both the pervasive effects of purifying selection at functionally-relevant sites in the genome and how this can interact with population history to lead to substantial local differentiation, even when standard metrics of structure such as F~ST~ are very small. The effect arises primarily because rare variants tend to be recent and thus tend to be geographically restricted^[@R6]-[@R8]^. The implication is that the interpretation of rare variants in individuals with a particular disease should be within the context of the local (either geographic or ancestry-based) genetic background. Moreover, it argues for the value of continuing to sequence individuals from diverse populations to characterise the spectrum of human genetic variation and support disease studies across diverse groups. A further 1500 individuals from 11 new populations, including at least 15 high-depth trios, will form the final phase of this project.

Methods summary {#S6}
===============

All details concerning sample collection, data generation, processing and analysis can be found in the [Supplementary Information](#SD1){ref-type="supplementary-material"}. [Fig. S1](#SD1){ref-type="supplementary-material"} summarises the process and indicates where relevant details can be found.
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![Power and accuracy\
**a**, Power to detect SNPs as a function of variant count (and proportion) across the entire set of samples, estimated by comparison to independent SNP array data in the exome (green) and whole genome (blue). **b**, Genotype accuracy compared to the same SNP array data as a function of variant frequency summarised by the *r*^2^ between true and inferred genotype (coded as 0, 1 and 2) within the exome (green), whole genome after haplotype integration (blue) and whole genome without haplotype integration (red).](ukmss-50091-f0001){#F1}

![The distribution of rare and common variants\
**a**, Summary of inferred haplotypes across a 100 kb region of chromosome 2 spanning the genes *ALMS1* and *NAT8*, variation in which has been associated with kidney disease^[@R45]^. Each row represents an estimated haplotype, with the population of origin indicated on the right. Reference alleles are indicated by the light blue background. Variants (non-reference alleles) above 0.5% frequency are indicated by pink (typed on the high density SNP array), white (previously known) and dark blue (not previously known). Low frequency variants (\<0.5%) are indicated by blue crosses. Indels are indicated by green triangles and novel variants by dashes below. A large, low-frequency deletion (black line) spanning *NAT8* is present in some populations. Multiple structural haplotypes mediated by segmental duplications are present at this locus, including copy number gains, which were not genotyped for this study. Within each population haplotypes are ordered by total variant count across the region. **b**, The fraction of variants identified across the project that are found in only one population (white line), are restricted to a single ancestry-based group (defined as in part A, solid colour), are found in all groups (solid black line) and are found in all populations (dotted black line). **c**, The density of the expected number of variants per kb carried by a genome drawn from each population, as a function of variant frequency (see [Supplementary Information](#SD1){ref-type="supplementary-material"}). Colours as for part a. Under a model of constant population size, the expected density is constant across the frequency spectrum.](ukmss-50091-f0002){#F2}

![Allele sharing within and between populations\
**a**, Sharing of *f*~2~ variants, those found exactly twice across the entire sample, within and between populations. Each row represents the distribution across populations for the origin of samples sharing an *f*~2~ variant with the target population (indicated by the left-hand side). The grey bar represents the average number of *f*~2~ variants carried by a randomly-chosen genome in each population. **b**, Median length of haplotype identity (excluding cryptically-related samples and singleton variants and allowing for up to two genotype errors) between two chromosomes that share variants of a given frequency in each population. Estimates are from 200 randomly-sampled regions of 1 Mb each and up to 15 pairs of individuals for each variant. **c**, The average proportion of variants that are novel (compared to the pilot phase of the project) among those found in regions inferred to have different ancestries within ASW, PUR, CLM and MXL. Error bars represent 95% bootstrap confidence intervals.](ukmss-50091-f0003){#F3}

![Purifying selection within and between populations\
**a**, The relationship between evolutionary conservation (measured by GERP score^[@R19]^) and rare variant proportion (fraction of all variants with derived allele frequency \< 0.5%) for variants occurring in different functional elements and with different coding consequences. Crosses indicate the average GERP score at variant sites (x-axis) and proportion of rare variants (y-axis) in each category. **b**, Levels of evolutionary conservation (mean GERP score, top) and genetic diversity (per nucleotide pairwise differences, bottom) for sequences matching the CTCF-binding motif within CTCF-binding peaks as experimentally identified by ChIP-Seq in the ENCODE project^[@R13]^ (blue) and in a matched set of motifs outside peaks (red). The logo plot shows the distribution of identified motifs within peaks. Error bars represent ± 2 s.e.m.](ukmss-50091-f0004){#F4}

![Implications of Phase 1 1000 Genomes data for GWAS\
**a**, Accuracy of imputation of genome-wide SNPs, exome SNPs and indels (using sites on the Illumina 1M array) into 10 individuals of African ancestry (3 LWK, 4 Masaai from Kenya - MKK, 2 YRI) sequenced to high coverage by an independent technology^[@R3]^. Only indels in regions of high sequence complexity with frequency \>1% are analysed. Deletion imputation accuracy estimated by comparison to array data^[@R46]^ (note this is for a different set of individuals though with a similar ancestry, but included on the same plot for clarity). Accuracy measured by squared Pearson correlation coefficient between imputed and true dosage across all sites in a frequency range estimated from the 1000 Genomes data. Lines represent whole genome SNPs (solid), exome SNPs (long dashes), short indels (dotted) and large deletions (short dashes). **b**, The average number of variants in linkage disequilibrium (*r*^2^\>0.5 among EUR) to focal SNPs identified in GWAS^[@R47]^ as a function of distance from the index SNP. Lines indicate the number of HapMap, Pilot and Phase 1 variants.](ukmss-50091-f0005){#F5}

![](ukmss-50091-f0006){#F6}

###### 

Summary of 1000 Genomes Phase 1 data

  ------------------------------------------------------------------------------------------------------------------------
                                                 Autosomes   Chromosome\          GENCODE\
                                                             X                    regions[a](#TFN1){ref-type="table-fn"}
  ---------------------------------------------- ----------- -------------------- ----------------------------------------
  **Samples**                                    1092        1092                 1092

  **Total raw bases (Gb)**                       19,049      804                  327

  **Mean mapped depth (x)**                      5.1         3.9                  80.3

  **SNPs**                                                                        

   No. sites overall                             36.7 M      1.3 M                498 K

   Novelty rate[b](#TFN2){ref-type="table-fn"}   58%         77%                  50%

   No. Syn / NonSyn /\                           NA          4.7 / 6.5 / 0.097\   199 / 293 / 6.3 K
   Nonsense                                                  K                    

   Avg. no. SNPs per sample                      3.60 M      105 K                24.0 K

  **Indels**                                                                      

   No. sites overall                             1.38 M      59 K                 1,867

   Novelty rate[b](#TFN2){ref-type="table-fn"}   62%         73%                  54%

   No. in-frame / frameshift                     NA          19 / 14              719 / 1,066

   Avg. no. indels per\                          344 K       13 K                 440
   sample                                                                         

  **Genotyped large deletions**                                                   

   No. sites overall                             13.8 K      432                  847

   Novelty rate[b](#TFN2){ref-type="table-fn"}   54%         54%                  50%

   Avg. no. variants per\                        717         26                   39
   sample                                                                         
  ------------------------------------------------------------------------------------------------------------------------

Autosomal genes only.

Compared to dbSNP release 135 (Oct 2011) excluding contribution from Phase 1 1000 Genomes (or equivalent data for large deletions).

###### 

Per individual variant load at conserved sites

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variant type                                          Number of derived variant\               Excess rare\   Excess low-\                                             
                                                        sites per individual                     deleterious    frequency\                                               
                                                                                                                deleterious                                              
  ----------------------------------------------------- ---------------------------------------- -------------- -------------- ----------------------------------------- -----------------------------------------
                                                        Derived allele frequency across sample                                                                           

                                                        \<0.5%                                   0.5%-5%        \>l5%                                                    

  **All sites**                                         30K-150K                                 120K-\         3.6M-\         \-                                        \-
                                                                                                 680K           3.9M                                                     

  **Synonymous** [a](#TFN5){ref-type="table-fn"}        29-120                                   82-420         1.3K-1.4K      \-                                        \-

  **Nonsynonymous** [a](#TFN5){ref-type="table-fn"}     130-400                                  240-910        2.3K-2.7K      76-190[b](#TFN6){ref-type="table-fn"}     77-130[b](#TFN6){ref-type="table-fn"}

  **Stop-gain** [a](#TFN5){ref-type="table-fn"}         3.9-10                                   5.3-19         24-28          3.4-7.5[b](#TFN6){ref-type="table-fn"}    3.8-11[b](#TFN6){ref-type="table-fn"}

  **Stop-loss**                                         1.0-1.2                                  1.0-1.9        2.1-2.8        0.81-1.1[b](#TFN6){ref-type="table-fn"}   0.80-1.0[b](#TFN6){ref-type="table-fn"}

  **HGMD-DM** [a](#TFN5){ref-type="table-fn"}           2.5-5.1                                  4.8-17         11-18          1.6-4.7[b](#TFN6){ref-type="table-fn"}    3.8-12[b](#TFN6){ref-type="table-fn"}

  **COSMIC** [a](#TFN5){ref-type="table-fn"}            1.3-2.0                                  1.8-5.1        5.2-10         0.93-1.6[b](#TFN6){ref-type="table-fn"}   1.3-2.0[b](#TFN6){ref-type="table-fn"}

  **Indel-frameshift**                                  1.0-1.3                                  11-24          60-66          \-[d](#TFN8){ref-type="table-fn"}         3.2-11[b](#TFN6){ref-type="table-fn"}

  **Indel-non-frameshift**                              2.1-2.3                                  9.5-24         67-71          \-[d](#TFN8){ref-type="table-fn"}         0-0.73[b](#TFN6){ref-type="table-fn"}

  **Splice site donor**                                 1.7-3.6                                  2.4-7.2        2.6-5.2        1.6-3.3[b](#TFN6){ref-type="table-fn"}    3.1-6.2[b](#TFN6){ref-type="table-fn"}

  **Splice site acceptor**                              1.5-2.9                                  1.5-4.0        2.1-4.6        1.4-2.6[b](#TFN6){ref-type="table-fn"}    1.2-3.3[b](#TFN6){ref-type="table-fn"}

  **UTR** [a](#TFN5){ref-type="table-fn"}               120-430                                  300-1.4K       3.5K-4.0K      0-350[c](#TFN7){ref-type="table-fn"}      0-1.2K[c](#TFN7){ref-type="table-fn"}

  **Non-coding RNA** [a](#TFN5){ref-type="table-fn"}    3.9-17                                   14-70          180 -200       0.62-2.6[c](#TFN7){ref-type="table-fn"}   3.4-13[c](#TFN7){ref-type="table-fn"}

  **Motif gain in TF**\                                 4.7-14                                   23-59          170-180        0-2.6[c](#TFN7){ref-type="table-fn"}      3.8-15[c](#TFN7){ref-type="table-fn"}
  **peak** [a](#TFN5){ref-type="table-fn"}                                                                                                                               

  **Motif loss in TF**\                                 18-69                                    71-300         580-650        7.7-22[c](#TFN7){ref-type="table-fn"}     37-110[c](#TFN7){ref-type="table-fn"}
  **peak** [a](#TFN5){ref-type="table-fn"}                                                                                                                               

  **Other conserved** [a](#TFN5){ref-type="table-fn"}   2.0K-9.9K                                7.1K-39K       120K-130K      \-                                        

  **Total conserved**                                   2.3K-11K                                 7.7K-42K       130K-150K      150-510                                   250-1.3K
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Only sites where ancestral state can be assigned with high confidence reported.

Ranges reported are across populations.

Sites with GERP\>2

Using Synonymous sites as base-line

Using 'Other conserved' as base-line

Rare indels were filtered in Phase 1
